Cadila Pharma launches the world’s first new 3-dose vaccine against rabies


Pharmaceutical giant Cadila Pharmaceuticals announced on Friday that it has developed the world’s first new three-dose rabies vaccine.

The three-dose vaccine, named “ThRabis,” is a nanoparticle-based recombinant G-protein vaccine that is prepared using Virus-like Particle technology, the company said in a statement, adding that the three-dose schedule is spread only over one week.



The new vaccine would be a game-changer as all existing rabies vaccines require five injections, spread over 28 days to eliminate the threat (of spreading the virus), Cadila Pharmaceuticals CMD Rajiv Modi said at the launch ceremony for the new vaccine.

“Victims of animal bites have not been able to complete the full course of the vaccine due to the long and complicated dosing schedule. This leaves many victims unprotected and susceptible to developing rabies, which is a fatal disease. With this new three-dose vaccine, many more lives can be saved,” he said.

It is estimated that globally, rabies kills 59,000 victims of animal bites each year, mainly in Asia and Africa. More than 20,000 people die in India alone, mainly because many animal bite victims do not complete the full course of available vaccine, the statement added.

According to data shared by the company, nearly 1.5 million people are victims of animal bites, mostly dogs, every year in India.

A survey found that only 30 lakh people, out of 1.5 crore victims of animal bites, approach doctors for rabies vaccinations. However, 30% of victims miss the fourth dose while almost 40% miss the last dose, which increases the risk of contracting a rabies infection.

The company said it took nearly 12 years to develop this three-dose vaccine, and the vaccine has been shown to be safe in clinical trials. The vaccine has been approved by the Drugs Controller General of India (DCGI).

In the first phase, the vaccine will be launched in 11 states including Gujarat. Company representatives are reportedly contacting nearly 6,000 physicians as part of their awareness campaign in those states.

The company has priced a vial at Rs 750 while the cost of the treatment, comprising three doses, would come to Rs 2,145, he added.

(Only the title and image of this report may have been edited by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear reader,

Business Standard has always endeavored to provide up-to-date information and commentary on developments that matter to you and that have wider political and economic implications for the country and the world. Your constant encouragement and feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these challenging times stemming from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative opinions and incisive commentary on relevant topical issues.
However, we have a request.

As we battle the economic impact of the pandemic, we need your support even more so that we can continue to bring you more great content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.

Support quality journalism and subscribe to Business Standard.

digital editor

About Cecil Cobb

Check Also

Graphic Novel Review: “Tristan Strong Punches a Hole in the Sky”

Kwame Mbalia’s dazzling story of Tristan Strong returns to book format in a stunning visual …